Company Overview
Snapshot
Founded in January 2020 by Moshe Golan, Kidod Science & Technologies operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its Virion Test, a noninvasive device for COVID-19 detection.
Business overview
Kidod Science & Technologies is a medical device company specializing in noninvasive diagnostic solutions. Its core product, the Virion Test, is designed to detect the COVID-19 virus in patient cells using a simple saliva sample. This device leverages ion mobility spectrometry technology to identify volatile chemicals, providing results in under a minute with high accuracy. The company operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices and digital healthcare markets.
Strategic signal
In August 2020, Kidod Science & Technologies partnered with CoreLogix Consulting to launch its rapid testing machine for COVID-19. This collaboration signals the company's strategic move to accelerate market entry and distribution for its Virion Test, indicating a focus on commercialization and broader accessibility for its diagnostic technology.
Company Intelligence Q&A
- What is the primary product developed by Kidod Science & Technologies?
- Kidod Science & Technologies has developed the Virion Test, a noninvasive detection device for the COVID-19 virus.
- When was Kidod Science & Technologies founded?
- Kidod Science & Technologies was founded in January 2020.
- What technology does the Virion Test utilize for detection?
- The Virion Test uses ion mobility spectrometry technology to trace volatile chemicals for COVID-19 detection from saliva samples.
- What was a key strategic partnership for Kidod Science & Technologies in 2020?
- In August 2020, Kidod Science & Technologies partnered with CoreLogix Consulting to launch its rapid testing machine for COVID-19.
- What is the accuracy and speed of the Virion Test?
- The Virion Test can analyze a sample and return results in less than 50 seconds with an accuracy of over 95%.